Skip to main content
Clinical Trials/NCT05006508
NCT05006508
Active, not recruiting
Not Applicable

Prevention and Development of Lifestyle Diseases With the Health and Lifestyle Tool

Region Skane1 site in 1 country77,000 target enrollmentAugust 16, 2021
ConditionsType2 Diabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type2 Diabetes
Sponsor
Region Skane
Enrollment
77000
Locations
1
Primary Endpoint
Incidence of type 2 diabetes
Status
Active, not recruiting
Last Updated
8 months ago

Overview

Brief Summary

In this study participants will be randomized to use a digital lifestyle tool over three years or to a control group without access to the tool. The investigators will prospectively via clinical registries follow the incidence and development of type 2 diabetes over three years in those using the tool regularly and those in the control group.

Detailed Description

Considerable evidence suggest that lifestyle changes can prevent or delay the onset of type 2 diabetes, and self-care behaviors largely determine HbA1c. Modifiable lifestyle factors have been established as key drivers of disease onset, progression, and prognosis, motivating the use of "lifestyle as medicine". Digital health tools are increasingly incorporated into diabetes care, and have the potential to improve both behavioral and clinical outcomes on a broad basis. However, low levels of uptake, reduced user engagement over time, and low acceptance among patients, raise concerns about their effectiveness. The objective or this study is to evaluate a new web-based tool, developed at the University Gothenburg, Sweden, that aims to support patient autonomy and motivation to make sustainable lifestyle changes. The investigators will test the hypothesis that individuals who have access to the tool get lower incidence of type 2 diabetes or in case they already have diabetes develop improved glucose control compared with control individuals. The participants will complete the Findrisc questionnaire to assess the risk for type 2 diabetes to enable analysis of individuals with different risk. The study is an investigator-initiated single-center study conducted over three years. The tool is web-based and used via a computer or mobile phone. It is used at each individual's preferred pace but participants are recommended to login at least every other week. Every round the participants choose a themes (out of appr. 150 possible covering e.g. food, exercise, stress, self-reflection aspects), which takes appr. 15-30 minutes to complete. Participants then reflect on the content and how it could be implemented in daily life. When returning for next round participants are asked to reflect on any changes done since last time. There is no interaction between individual participants. There will be two primary endpoints: 1. Incidence of type 2 diabetes as measured in non-diabetic participants with different risk for type 2 diabetes (controls vs. those using the tool regularly) 2. Change of HbA1c, reflecting long-term blood glucose control, from baseline to end of follow-up in participants who have type 2 diabetes (controls vs. those using the tool regularly).

Registry
clinicaltrials.gov
Start Date
August 16, 2021
End Date
December 31, 2026
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • informed consent
  • Age above 35 years

Exclusion Criteria

  • type 1 diabetes, MODY or secondary diabetes
  • conditions or treatments that in the judgement of the Investigator could affect the study evaluation
  • connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.

Outcomes

Primary Outcomes

Incidence of type 2 diabetes

Time Frame: 3 years

Incidence of type 2 diabetes defined as random plasma glucose \>11.1 mmol/L or fasting glucose \>7.0 mmol/L or HbA1C ≥6.5% compared between participants regularly using the tool and on usual care.

Change of long-term blood glucose concentration measured as glycated hemoglobin at end of follow-up

Time Frame: 3 years

Intraindividual change of long-term blood glucose concentration measured as glycated hemoglobin (HbA1c) at end of follow-up relative to baseline compared between participants regularly using the tool and on usual care.

Prescription of anxiolytic medication

Time Frame: 3 years

Number of participants on prescription of anxiolytic medication between participants regularly using the tool and on usual care.

Prescription of antidepessive medication

Time Frame: 3 years

Number of participants on prescription of antidepressive medication between participants regularly using the tool and on usual care.

Secondary Outcomes

  • Change of Anxiety estimated by General Anxiety Disorder 7-item scale(1 year)
  • Change of Patient Health Questionnaire 9-item scale(1 year)

Study Sites (1)

Loading locations...

Similar Trials